<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059770</url>
  </required_header>
  <id_info>
    <org_study_id>Three L-AmB Regimens in Histo</org_study_id>
    <nct_id>NCT04059770</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients</brief_title>
  <official_title>Open Label Phase-II Randomized Trial of Three Liposomal Amphotericin B Regimens as Induction Therapy for Disseminated Histoplasmosis in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alessandro Pasqualotto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nossa Senhora da Conceicao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Health Science of Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disseminated histoplasmosis (DH) is one of the major AIDS-defining infections responsible for
      high mortality rates in HIV-infected patients. Liposomal amphotericin B (L-AmB) is considered
      the therapy of choice for AIDS-associated histoplasmosis.However, many patients in Latin
      America are still treated with high doses of deoxycholate amphotericin B (d-AmB) for long
      periods. These regimens are associated with toxicity and thus reduced efficacy. Therefore, a
      better treatment strategy is necessary to improve the activity of this amphotericin B
      treatment. Treatment with a high dose of L-AmB for short periods (rather than standard doses
      for longer periods) is a promising approach considering that the antifungal effect of
      amphotericin B depends on peak concentrations. This randomized open-label Phase II study aims
      to determinate and to compare the activity and safety of three L-AmB regimens, as induction
      therapy for DH in AIDS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized non-comparative multicenter open label trial of induction
      therapy with LAmB for DH in AIDS patients, followed by oral therapy with itraconazole.

      The sample size planned is 99 patients of both sexes, older than 18 years (33 patients per
      study arm), infected with HIV and with confirmed diagnosis for DH. This sample size considers
      10% of dropout.

      The study will be conducted in accordance with the Helsinki Declaration, as well as the
      Standards national and international Guidelines for Good Clinical Practices.

      Eight research centres in Brazil will competitively recruit patients: Santa Casa de
      Misericórdia de Porto Alegre (Porto Alegre; Dr Alessandro C. Pasqualotto), Hospital de
      Clínicas de Porto Alegre (Porto Alegre; Dr Diego R. Falci), Hospital Nossa Senhora da
      Conceição (Porto Alegre; Dr Marineide Melo), Hospital de Doenças Tropicais (Goiânia; Dr
      Cassia S. de Miranda Godoy), Hospital São José de Doenças Infecciosas (Fortaleza; Dr
      Terezinha M. J. Silva Leitão), and Hospital Giselda Trigueiro (Natal, Dr Monica B. Bay),
      Hospital Universitário Osvaldo Cruz (Recife, Dr. Filipe Prohaska Batista) e Instituto de
      Infectologia Emília Ribas (São Paulo, Dr. José Ernesto Vidal Bermudez).

      AIDS patients with DH will be randomized to one of three study arms:

      (i) single IV dose of 10 mg/kg of L-AmB; (ii) single IV dose of 10 mg/kg of L-AmB on day 1,
      followed by 5 mg/kg of L-AmB on day 3; (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.

      Induction therapy will be followed in all patients by oral therapy with itraconazole capsules
      at 400 mg/daily for a year, azole drug which is already therapy of choice for consolidation
      of histoplasmosis, according to national and international Guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>day 14</time_frame>
    <description>Maximum daily temperature lower than 37.8 °C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight stability</measure>
    <time_frame>day 14</time_frame>
    <description>This parameter will be measurement by a questionnaire, based on information about the patient weight in kilograms (Kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>day 14</time_frame>
    <description>Analysis if any patient presented hypotension (systolic blood pressure ˂ 90 mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood oxygen level</measure>
    <time_frame>day 14</time_frame>
    <description>Normal arterial oxygen is approximately 75 to 100 millimeters of mercury (mm Hg). Values under 60 mm Hg usually indicate the need for supplemental oxygen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>day 14</time_frame>
    <description>Mortality rates attributed to the cause of death that is not directly and only related to histoplasmosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to histoplasmosis</measure>
    <time_frame>day 14</time_frame>
    <description>Mortality rates attributed by the study investigator that are directly related to histoplasmosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function abnormalities</measure>
    <time_frame>day 14</time_frame>
    <description>Microalbuminuria &gt; 30 mg/24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function abnormalities</measure>
    <time_frame>day 14</time_frame>
    <description>Liver function abnormalities were serum levels of alanine and aspartate aminotransferase &gt; 2.5 times normal or bilirubin levels &gt; 2 times normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histoplasma urinary antigen concentrations</measure>
    <time_frame>day 7, 14</time_frame>
    <description>Decrease of at least 50% in Histoplasma urinary antigen concentrations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Histoplasmosis</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>single dose of L-AmB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single IV dose of 10 mg/kg of L-AmB on day 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses of L-AmB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 weeks of L-AmB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV dose of 3 mg/kg of L-AmB for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of L-AmB</intervention_name>
    <description>(i) single IV dose of 10 mg/kg of L-AmB on day 1;</description>
    <arm_group_label>single dose of L-AmB</arm_group_label>
    <other_name>Intervention 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 doses of L-AmB</intervention_name>
    <description>(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;</description>
    <arm_group_label>2 doses of L-AmB</arm_group_label>
    <other_name>Intervention 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 weeks of L-AmB</intervention_name>
    <description>(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.</description>
    <arm_group_label>2 weeks of L-AmB</arm_group_label>
    <other_name>Intervention 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 18 years) HIV-infected hospitalized patients diagnosed with HD by the means
             of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii)
             confirmation by classical mycological methods (microscopy, culture or histopathology);
             or (iii) Histoplasma positive qualitative polymerase chain reaction (PCR) in
             bronchoalveolar lavage samples, bone marrow aspirates or tissue samples.

          -  Patients will be included despite of the use of antiretroviral therapy (ART).

          -  Understanding and signed the Informed Consent Form.

        Exclusion Criteria:

          -  Patients with previous diagnosis of histoplasmosis.

          -  Pregnant or lactating women.

          -  Patients with renal insufficiency (serum creatinine and urea &gt; 1.5x the upper limit of
             normal).

          -  Abnormal aminotransferases (up to &gt; 3x the upper limit of normal) and patients with a
             severe prior reaction to polyene antifungal.

          -  Patients who have received more than one dose of a polyene antifungal in the last 48
             hours.

          -  Patients who refuse to participate in the study.

          -  Patients diagnosed with histoplasmosis that affect the central nervous system.

          -  Patients who, at the trial of the attending physician, are expected to die within 48
             hours.

          -  Patients diagnosed with tuberculosis.

          -  Patients with any disease or condition that, in the opinion of the investigator, may
             interfere with the assessments or participation in the study.

          -  Patients receiving drugs that cause significant (relative or absolute) drug
             interaction with Itraconazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiane Dalla Lana, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro C. Pasqualotto, MD PhD</last_name>
    <phone>55 51 999951614</phone>
    <email>acpasqualotto@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cássia Caurio</last_name>
    <phone>55 51 995888081</phone>
    <email>cassiacaurio@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Health Science of Porto Alegre</investigator_affiliation>
    <investigator_full_name>Alessandro Pasqualotto</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <keyword>AIDS</keyword>
  <keyword>Liposomal amphotericin B</keyword>
  <keyword>High dose therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

